Cancer
US FDA approves HPV vaccine for men and women aged 27-45
October 8, 2018Sales and Marketing CDC, Cancer, FDA, HPV, approval, infectious diseases, vaccines
The US Food and Drug Administration have approved the use of HPV vaccine Gardasil 9 for both men and woman …
Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer
October 3, 2018Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma
The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …
No link between progression-free survival benefits and improved quality of life, study argues
October 2, 2018Manufacturing and Production, Research and Development Cancer, clinical trials, pharma
A study of randomised clinical trials, conducted by Canada’s McMaster University and published in the Journal of the American Medical …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
Nobel Prize awarded to immuno-oncology innovators
October 2, 2018Manufacturing and Production Cancer, Nobel Prize, immunotherapy, kyoto, oncology, texas
The Nobel Prize for physiology or medicine has been awarded to both Professor James P Allison and Tasuku Honjo for …
Ipsen appoints two leading R&D experts in bid to strengthen oncology arm
September 28, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, R&D, development, ipsen, oncology, research
French pharma firm Ipsen has announced the appointment of Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic …
Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer
September 26, 2018Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …
NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
Roche’s entrectinib shrinks lung tumours with two-year response duration
September 25, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …
AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer
September 25, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …
Cancer Research UK announces new £14m research hub in London
September 18, 2018Manufacturing and Production, Research and Development CRUK, Cancer, pharma
Cancer Research UK has announced a £14 million investment to build a new hub in London for cancer research and …
NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma
September 17, 2018Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma
NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …
Merck KGaA and Pfizer’s combo impresses in first-line treatment of advanced kidney cancer
September 12, 2018Research and Development, Sales and Marketing Cancer, Kidney cancer, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 10, 2018Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …
A rational new approach to cancer treatment
September 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, University of East Anglia, feature, pharma
Researchers at the University of East Anglia have developed a new targeted cancer therapy which utilises nanoparticles to deliver treatment …
Latest content
Five Facts about cardiovascular disease
